Targeting GRPR in urological cancers--from basic research to clinical application

Area of Science:

• Oncology
• Radiochemistry
• Molecular Imaging

Background:

• Gastrin releasing peptide (GRP) is a regulatory peptide.
• Its receptor, GRPR, is overexpressed in prostate and renal cell cancers, and urinary tract cancer tumoral vessels.
• Targeting GRPR offers potential for cancer diagnosis and therapy.

Purpose of the Study:

• To design and test GRP analogues for targeting GRPR-expressing tumors.
• To evaluate radioactive, cytotoxic, and nonradioactive GRP analogues for diagnostic and therapeutic applications.
• To assess the clinical potential of GRP analogues in cancer treatment.

Main Methods:

• Design and synthesis of potent and specific GRP analogues (radioactive, cytotoxic, nonradioactive).
• Testing of GRP analogues in various animal tumor models.
• Clinical studies of radioactive GRP analogues (agonists and antagonists).

Main Results:

• All tested GRP analogue categories demonstrated suitability for tumor targeting in animal models.
• Cytotoxic and nonradioactive GRP analogues have not yet shown significant tumor reduction in human trials.
• Early clinical studies indicate radioactive GRP analogues are promising for diagnostic imaging and radiotherapy.

Conclusions:

• GRP analogues are viable candidates for GRPR-targeted cancer diagnosis and therapy.
• Radioactive GRP analogues show significant clinical potential for imaging and treating prostate and other GRPR-expressing cancers.
• Further clinical investigation of GRP analogues is warranted.